Company intelligence / Profile preview

Amunix Pharmaceuticals

South San Francisco, California, United Statesamunix.com ↗

Ownership: Private
Employees: ~39
Development stage: Other

Overview

Amunix has developed a pipeline of masked T cell engagers and cytokines using its proprietary Pro-XTEN/XPAT/XPAC platforms. The lead candidate, AMX‑818, targets HER2-expressing solid tumors and is in IND-enabling studies. Other programs include PSMA-XPAT and EGFR-XPAT. The company’s masking technology aims to reduce toxicity by activating drugs preferentially within the tumor microenvironment. Clinical results are not yet available as the main candidates are preclinical or entering early clinical development.

Therapeutic areas: Oncology
Modalities: T cell engagers (TCEs)CytokinesBi-specific antibodies
Industry: Biotech

Partnerships

Roche (licensing deal worth up to $1.5 billion; $40 million upfront)Sanofi (acquirer and current parent company)

Beyond the preview

Go deeper on Amunix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amunix Pharmaceuticals.